Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DB2VY6
|
|||
| Drug Name |
VH4011499
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62] | Phase 1 | [1] | |
| Company |
GlaxoSmithKline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Capsid p24 (HIV p24) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05393271) A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Administered VH4011499 in Healthy Participants. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of ViiV Healthcare | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.